TrialInternational journal of clinical oncology2019

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.

Norikazu Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.